STOCK TITAN

Marker Therapeut - MRKR STOCK NEWS

Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.

Marker Therapeutics Inc (MRKR) is a clinical-stage biotechnology company pioneering novel T cell-based immunotherapies and peptide vaccines for hematological cancers and solid tumors. This news hub provides investors and researchers with timely updates on MRKR's advancements in cancer treatment innovation.

Access comprehensive coverage of Marker Therapeutics' developments, including clinical trial progress, strategic partnerships, and regulatory milestones. Our curated news ensures you stay informed about key initiatives in immuno-oncology without promotional bias.

Key updates include MultiTAA technology advancements, NIH-funded research programs, financial disclosures, and scientific presentations. We track both therapeutic breakthroughs and operational developments critical for evaluating MRKR's position in the competitive biotech landscape.

Bookmark this page for streamlined access to verified Marker Therapeutics updates. For comprehensive analysis of MRKR's pipeline and market potential, visit Stock Titan regularly.

Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nationwide multi-center Phase 1 APOLLO study, evaluating the safety and efficacy of MT-601, a multi-tumor associated antigen-specific T cell product.

The company has now received over $19 million in non-dilutive funding. Preliminary results from the APOLLO study show objective responses in all three study participants treated at City of Hope, with no cytokine release syndrome or immune effector cell associated neurotoxicity syndrome observed. This grant supports Marker's efforts to address the unmet medical need for patients who relapse after CD19-targeting CAR-T cell therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
-
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) reported first quarter 2024 financial results and business updates. The company highlighted continued clinical progress, noting promising results in its Phase 1 APOLLO study of MT-601 for lymphoma. Significant milestones include sustained complete responses in study participants and an official nonproprietary name 'neldaleucel' for MT-601. Financially, Marker saw a reduction in R&D and G&A expenses, narrowing its net loss to $2.4 million from $4.9 million year-over-year. Cash and cash equivalents stood at $11.3 million, expected to fund operations into Q4 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
-
Rhea-AI Summary
Marker Therapeutics, Inc. presents promising preliminary data from the APOLLO study at the 11th Global Summit on Hematologic Malignancies. The study focuses on MT-601, a multiTAA-specific T cell product, for lymphoma patients who failed anti-CD19 CAR T cell therapy. Results show durable objective responses and sustained complete responses, highlighting potential benefits of MT-601.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences clinical trial
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) reports positive results in lymphoma program with sustained complete response, secures $2 million NIH funding for AML program, receives ODD from EMA for AML treatment, appoints new leadership, and executes non-dilutive agreement with Cell Ready to reduce expenses and extend runway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.74%
Tags
-
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) announced that its CEO, Juan Vera, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024, discussing the company's advancements and clinical development programs. The conference will provide insights into Marker's business and future milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
conferences
-
Rhea-AI Summary
Nimbus Therapeutics appoints Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of pharmaceutical research and development experience. Dr. Knobil's expertise will aid in accelerating Nimbus' development programs in oncology, immunology, and metabolism, aiming to bring novel therapies to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
management
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) announced the approval of 'neldaleucel' as the nonproprietary name for MT-601, a T cell product candidate for the treatment of lymphoma. The approval signifies a significant milestone in the development of multiTAA therapies, following positive clinical safety and durability results in the Phase 1 study. Juan Vera, M.D., President and CEO of Marker Therapeutics, expressed the importance of the approval in advancing potential treatments for patients with lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
-
Rhea-AI Summary
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced strategic prioritization of clinical programs with a focus on MT-601 in patients with lymphoma. The company also provided updates supporting the clinical benefits of MT-401 in patients with measurable residual disease (MRD) in acute myeloid leukemia (AML).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
-
Rhea-AI Summary
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced its participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit alongside the J.P. Morgan 42nd Annual Healthcare Conference 2024. The company secured over $17 million in non-dilutive funding and will present at the summit. Members of the management team will also conduct one-on-one meetings with investors during J.P. Morgan week.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
Rhea-AI Summary
Marker Therapeutics, Inc. (MRKR) reports positive clinical update on APOLLO study, with patient maintaining complete response six months after MT-601 treatment for relapsed Non-Hodgkin’s Lymphoma following anti-CD19 CAR T cell therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.73%
Tags
none
Marker Therapeut

Nasdaq:MRKR

MRKR Rankings

MRKR Stock Data

12.32M
9.65M
9.85%
41.81%
1.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON